News
REVBW
0.0077
+18.46%
0.0012
Weekly Report: what happened at REVBW last week (0928-1002)?
Weekly Report · 10/05 09:59
Weekly Report: what happened at REVBW last week (0921-0925)?
Weekly Report · 09/28 09:55
Weekly Report: what happened at REVBW last week (0914-0918)?
Weekly Report · 09/21 09:55
Weekly Report: what happened at REVBW last week (0907-0911)?
Weekly Report · 09/14 09:59
Weekly Report: what happened at REVBW last week (0831-0904)?
Weekly Report · 09/07 09:54
Weekly Report: what happened at REVBW last week (0824-0828)?
Weekly Report · 08/31 09:59
Weekly Report: what happened at REVBW last week (0817-0821)?
Weekly Report · 08/24 10:00
Weekly Report: what happened at REVBW last week (0810-0814)?
Weekly Report · 08/17 10:01
Weekly Report: what happened at REVBW last week (0803-0807)?
Weekly Report · 08/10 09:57
Weekly Report: what happened at REVBW last week (0727-0731)?
Weekly Report · 08/03 09:57
Weekly Report: what happened at REVBW last week (0720-0724)?
Weekly Report · 07/27 10:00
Weekly Report: what happened at REVBW last week (0713-0717)?
Weekly Report · 07/20 09:57
Weekly Report: what happened at REVBW last week (0706-0710)?
Weekly Report · 07/13 09:59
Weekly Report: what happened at REVBW last week (0629-0703)?
Weekly Report · 07/06 10:01
Weekly Report: what happened at REVBW last week (0622-0626)?
Weekly Report · 06/29 09:58
Weekly Report: what happened at REVBW last week (0615-0619)?
Weekly Report · 06/22 10:04
Weekly Report: what happened at REVBW last week (0608-0612)?
Weekly Report · 06/15 10:05
Weekly Report: what happened at REVBW last week (0601-0605)?
Weekly Report · 06/08 10:02
Weekly Report: what happened at REVBW last week (0525-0529)?
Weekly Report · 06/01 10:05
Weekly Report: what happened at REVBW last week (0518-0522)?
Weekly Report · 05/25 10:08
More
Webull provides a variety of real-time REVBW stock news. You can receive the latest news about Rvltn Bioscnc through multiple platforms. This information may help you make smarter investment decisions.
About REVBW
Revelation Biosciences, Inc. is a clinical-stage life sciences company engaged in the development of innate immune system therapeutics and diagnostics. Its therapeutic candidates are based on its Gemini formulation of active ingredient phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA) that is known to stimulate Toll-like receptor 4 (TLR-4). Its product candidates include Gemini-SSI, which is being developed for the prevention and treatment of surgical sit infection; Gemini-AKI, which is being developed as a potential therapy for the prevention and treatment of acute kidney injury as a result of cardiac surgery; and Gemini-CKD, which is being developed as a potential therapy for the prevention and treatment of chronic kidney disease. Stimulation of TLR4 via Gemini leads to a controlled production of varied cytokines and chemokines which modulate the activity of the innate and adaptive immune response, relative to Lipopolysaccharides (LPS).